MolPharm

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by GALARDY, R. E.
Right arrow Articles by JAMIESON, J. D.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by GALARDY, R. E.
Right arrow Articles by JAMIESON, J. D.

Molecular Pharmacology, Vol 13, 852-863, Copyright © 1977 by the American Society for Pharmacology and Experimental Therapeutics

Photoaffinity Labeling of a Peptide Secretagogue Receptor in the Exocrine Pancreas

RICHARD E. GALARDY 1 and JAMES D. JAMIESON 1

1 Section of Cell Biology, Yale University School of Medicine, New Haven, Connecticut 06150

The photoaffinity label 2-nitro-5-azidobenzoyl-Gly-Trp-Met-Asp-Phe-NH2 (NAB-CCK-5) mimics cholecystokinin and the more potent secretagogue cerulein in stimulating discharge of exportable proteins from acinar cells of the guinea pig pancreas in vitro. Photolysis of this affinity label in the presence of pancreatic lobules (small clusters of acini) causes irreversible stimulation of protein discharge which is indistinguishable in rate, magnitude, and morphological aspects from that observed with the most potent doses of cerulein. The irreversible agonist activity cannot be removed by extensive washing of the lobules, and is blocked only by metabolic inhibition. Irreversible agonist activity is not observed without photolysis, nor is it observed after photolysis of lobules in the presence of 2-nitro-5-azidobenzoic acid, 2-nitro-5-azidobenzoyl-angiotensin II, 2-nitro-5-azidobenzoyl-Gly-Gly-Met-Asp-Phe-NH2, or cerulein, or with previously photolyzed NAB-CCK-5. Protection by native peptide secretagogues against irreversible labeling by NAB-CCK-5, however, could not be demonstrated. Although the biologically active sites which we have labeled appear to be those responsible for peptide secret-agogue-mediated release of exportable proteins, the absence of competition by native secretagogues for labeling shows that the mechanism of labeling NAB-CCK-5 is not understood at this time.

Note:
ACKNOWLEDGMENTS The authors are grateful to Ms. Betty Tai and Ms. Mary Lee Schaefer for excellent technical assistance.

Submitted on June 25, 1976
Accepted on May 4, 1977




This article has been cited by other articles:


Home page
 J. Biol. Chem.Home page
M. Dong, X.-Q. Ding, D. I. Pinon, E. M. Hadac, R. P. Oda, J. P. Landers, and L. J. Miller
Structurally Related Peptide Agonist, Partial Agonist, and Antagonist Occupy a Similar Binding Pocket within the Cholecystokinin Receptor. RAPID ANALYSIS USING FLUORESCENT PHOTOAFFINITY LABELING PROBES AND CAPILLARY ELECTROPHORESIS
J. Biol. Chem., February 19, 1999; 274(8): 4778 - 4785.
[Abstract] [Full Text] [PDF]


Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
Molecular Interventions Drug Metabolism and Disposition

Copyright © 1977 by the American Society for Pharmacology and Experimental Therapeutics